Venrock Discloses 9.9% Stake in Korsana Biosciences After Reverse Merger
CYCN is trading near its 52-week low of $7.186 (52% below the low) on elevated volume (37× avg).
Summary
Venrock Healthcare Capital Partners disclosed a 9.9% stake in Korsana Biosciences following the reverse merger, with $134.8 million invested in the company's predecessor and board representation through partner Nimish Shah.
Key Events · Ownership and Investor Activity · CYCN
-
Venrock Discloses 9.9% Stake
Venrock Healthcare Capital Partners entities collectively hold 4,552,277 shares of Korsana Biosciences, representing 9.9% of outstanding common stock, subject to a 9.99% beneficial ownership blocker.
-
$134.8M Investment in Predecessor
Between November 2024 and the merger closing, Venrock entities invested $134,843,200 in Old Korsana securities, including Series Seed preferred stock, Series A preferred stock, common stock, and pre-funded warrants.
-
Board Representation
Venrock partner Nimish Shah serves on the board of directors of Korsana Biosciences and was granted a stock option to purchase 48,455 shares of common stock on September 9, 2026.
-
Lock-Up Agreement
Venrock entities are subject to lock-up agreements restricting sales of Korsana securities until 180 days after the merger closing, which occurred on September 8, 2026.
Analysis · CYCN · Life Sciences
A prominent life sciences venture capital firm, Venrock Healthcare Capital Partners, has disclosed a 9.9% beneficial ownership stake in Korsana Biosciences following the company's reverse merger with Cyclerion Therapeutics. The filing reveals that Venrock entities invested $134.8 million in Old Korsana securities between November 2024 and the merger closing, and now hold 4,552,277 shares of the combined company. The stake is subject to a 9.99% beneficial ownership blocker, and Venrock partner Nimish Shah serves on the board of directors. This disclosure provides important context about the ownership structure of the newly merged company and the confidence of a major healthcare investor in Korsana's Alzheimer's disease pipeline.
How filings like this one have moved
In the 30 days to Nov 2, 2026, 32.7% of the 1910 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CYCN was trading at $3.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15.7M. The 52-week trading range was $7.19 to $59.36. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.